Spyre Therapeutics Q3 net loss widens to $96.12 million

• Spyre Therapeutics’ third-quarter 2026 net loss widened year over year to $96.12 million.
• Research and development expenses rose 97% to $89.17 million, driven by higher manufacturing costs and clinical trial expenses.
• Cash, cash equivalents and marketable securities totaled $1.07 billion at September 30; expected funding runway extends into the second half of 2029.
• SKYLINE combination-trial enrollment exceeded expectations, enabling a higher enrollment target; topline induction results remain expected in the third quarter of 2027.
• SPY072 will not advance in rheumatic diseases following insufficient benefit in rheumatoid arthritis and missed primary endpoints in two other sub-studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031601PRIMZONEFULLFEED9869141) on November 03, 2026, and is solely responsible for the information contained therein.